IP Library Granted Patent US 9,719,127
Granted Patent B2
US 9,719,127 · App. 14/385,824 · Granted Aug 1, 2017

Dual inducible vectors and cell lines

Inventors: Benhur Lee (Los Angeles, CA); Kelechi Chikere (Los Angeles, CA); Tom Chou (Venice, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
C12Q1/66C12N5/0686C12Q1/6897C12Q1/703C12N2740/16031C12N2840/60G01N2333/163
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,719,127
App. No.
14/385,824
Granted
Aug 1, 2017
Kind
B2
Abstract

The invention pertains to a novel cell line, an HIV tat-rev dependent GFP-Gaussia luciferase Reporter cell line, known henceforth as the GGR cell line, that detects pseudotype and replication competent HIV (cloned or uncloned isolates, in cell media or human serum) rapidly and with high sensitivity. This GGR cell line provides an improved method of characterizing the entry phenotype of HIV envelope genes, and detecting and examining primary HIV samples in the context of laboratory research, clinical trial monitoring, and medical diagnostics. Examples include, but are not limited to, determining the functional HIV viral load, responsiveness to treatment, characterization of viral co-receptor usage (testing for viral co-receptor usage, i.e., CCR5 vs CXCR4, as required prior to prescribing FDA-approved CCR5 inhibitors), and characterization of other viral or drug resistance phenotypic properties to guide treatment.

Claims (8)

1. A vector comprising the transactivators of the tetracycline and ponasterone inducible systems and the FRT-LacZeo selection cassette wherein the vector allows inducible expression of two genes of interest and a high expression of the selectable markers LacZ and Zeocin, wherein the transactivator of tetracycline is operably linked to VGECR of the transactivator of ponasterone by a P2A ribosome skipping sequence, and wherein a RSV 5′ LTR promoter is operably linked to RKR of the transactivator of ponasterone.

2. The vector according to claim 1 , wherein the vector is represented in FIG. 13 .

3. A cell line comprising the vector identified in claim 1 .

4. A method for creating a cell line that can be made to regulate the expression of any two genes placed under the respective inducible promoter comprising transfecting a cell with the vector of FIG. 13 .

5. A vector as set forth in FIG. 32 .

6. A cell line comprising the vector identified in claim 5 .

7. A cell line created from the method according to claim 4 .

8. A method for controlling the expression of any two genes of interest comprising transfecting a cell with the vector of FIG. 13 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2016
From: LEE, BENHUR; CHIKERE, KELECHI; CHOU, TOM
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 038569/0167 →
CONFIRMATORY LICENSE Recorded May 27, 2015
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035782/0639 →
Continuity (2)
Provisional Application 61613129 · Mar 20, 2012
Related Publication 20150125850A1 · May 7, 2015